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a b s t r a c t
Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It
is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly
evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in
tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought
to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-
progression. This review explores the possibility of bimodal treatment combining radiotherapy with
immunotherapy.





r é s u m é
La radiothérapie, conjointement avec la chirurgie et la chimiothérapie, est une thérapeutique majeure du
cancer. Elle est délivrée dans la tumeur primitive en situation néo-adjuvante ou adjuvante. Les techniques
de radiothérapie ont beaucoup évolué au cours de la dernière décennie en autorisant la délivrance de
fortes doses et en réduisant les effets secondaires dans les tissus sains adjacents. Sans oublier le contrôle
de la tumeur, des efforts doivent être faits pour contrôler la maladie macroscopique et celle à distance, qui
est finalement responsable de la progression tumorale. Cette revue traite de la possibilité d’association
de radiothérapie et d’immunothérapie.
© 2014 Société française de radiothérapie oncologique (SFRO). Publié par Elsevier Masson SAS. Tous. Stereotactic ablative body radiotherapy
Stereotactic ablative body radiotherapy is a form of high-
recision radiotherapy delivering extremely high ablative doses
f radiation, usually in three to eight fractions, combining
eproducible patient immobilization, tumour motion tracking and
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steep dose gradients, resulting in reduced normal tissue toxicity
[1]. Stereotactic ablative body radiotherapy achieves excellent local
control rates in patients with stage I/II non-small cell lung can-
cer and liver metastases of colorectal cancer [2]. Nowadays, these
favourable results of stereotactic ablative body radiotherapy are
being transferred to patients with limited sites of metastatic dis-
ease (oligometastatic; five or less metastases in no more than three
organs) originating from solid tumours (e.g., breast, non-small cell
lung cancer, head and neck, renal cell carcinoma, melanoma, colo-
rectal cancer), both at primary diagnosis (synchronous) and during
the course of disease [3–10]. Tree et al. reports on favourable
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ocal control rates of approximately 80% using stereotactic ablative
ody radiotherapy with few treatment-related side-effects [10].
ecently, our group found patients suffering from non-small cell
ung cancer with synchronous oligometastases to have a median
rogression-free survival of 12.1 months when treated radically
o all known metastatic sites [11]. However, in the vast major-
ty of patients, disease-progression at distance from the treated
ite occurs ultimately leading to extensive metastatic disease and
ancer-related death.
. Tumorigenesis and the immune system
The immune system closely monitors the process of tumorigen-
sis first by registering the presence of cells undergoing neoplastic
ransformation, and second by interacting with neoplastic cells to
ediate their destruction. Solid tumours have developed mech-
nisms to escape “cancer immunosurveillance”, i.e., detection by
he immune system. This is achieved by, among other mecha-
isms, the secretion of potent immune-suppressive cytokines and
he expression of T cell inhibitory molecules, which are able to
own-regulate an anti-tumour immune response [12]. There is
onclusive evidence that, apart from its direct effects, radiothe-
apy can induce “immunogenic cell death”, which serves as a
rigger or “in situ vaccine” for the innate and adaptive immune
ystem [13–15]. Radiotherapy induces immunogenic cell death by
he release of tumour antigens and damage-associated molecu-
ar patterns (DAMPS), including high-mobility group protein B1
HMGB1), adenosine triphosphate (ATP) and the exposure of cal-
eticulin on the tumour cell surface. Also, several cellular surface
xpression molecules, including Fas and ICAM-1, are upregulated
16,17]. These factors promote uptake of dying cells by dendritic
ells, cross-presentation of tumour antigens to T cells, and activa-
ion of anti-tumour (cytotoxic) T cells [18,19] (Fig. 1).
Recent preclinical and clinical data indicate that immunogenic
ell death may be an important consequence of ionizing radia-
ion and that localized radiotherapy can evoke and/or modulate
umour-associated immune responses [18,20]. Even though clinical
vidence of systemic anti-tumour response from local irradia-
ion is scarce, tumour regression outside the irradiated field was
lready recognized in 1953 and termed abscopal effect [21–25].
n general, it is unlikely that radiotherapy alone provides a suf-
cient anti-tumour immune response and the addition of active
mmunotherapy to stereotactic ablative body radiotherapy may
ncrease the therapeutic potential and induce abscopal effects in
more systematic way [24,26].
. Recent clinical successes using immunotherapy
.1. Breaking the immune tolerance using checkpoint modulators
Immune-checkpoints refer to a plethora of inhibitory pathways
ardwired into the immune system. These are crucial for main-
aining self-tolerance and modulating the duration and amplitude
f physiological immune responses in peripheral tissues, in order
o minimize collateral tissue damage. It is now clear that tumours
se certain immune-checkpoint pathways as a major mechanism
f immune resistance, particularly against tumour antigen specific
cells. Examples of these immune-checkpoints are the cytotoxic
lymphocyte-associated antigen 4 (CTLA-4), or the programmed
eath receptor 1 (PD-1) and its ligand PD-L1. New strategies aim at
reaking this tolerance.Monoclonal antibody-mediated (ipilimumab) blockade of CTLA-
on T cells seems to be sufficient to elicit an effective anti-tumour
mmunity [27], which paved the way for clinical studies. Two-phase
II studies evaluated the clinical effects of ipilimumab in metastaticérapie 18 (2014) 391–395
melanoma patients. Treatment with ipilimumab as monotherapy
improved median overall survival rates from 6.4 to 10 months
[28], and bimodal treatment with standard of care chemotherapy
(dacarbazine) increased 3-year overall survival from 12.2% to 20.8%
[29]. Although the percentage of patients responding to ipilimumab
was limited (complete response ∼1%, partial response in 5–10%),
the effects of response were long-lasting in those who responded.
Even though treatment-related adverse effects occurred in almost
all patients, with several immune effects-related deaths in the first
trial, and despite the high costs, ipilimumab received FDA approval
in 2011 for treatment of advanced melanoma patients due to its
clear clinical effect.
3.2. Immunotherapy for other solid tumours
The effect of immunotherapy has increasingly been evalu-
ated in both immunogenic and non-immunogenic (metastatic)
solid tumours, including prostate cancer, renal cell carcinoma,
melanoma, and head and neck cancer. In the subsequent paragraph
the diversity and recent merits of this approach are highlighted.
The autologous active cellular immunotherapy, Sipuleucel-T,
significantly reduced the risk of death in patients suffering from
metastatic castration-resistant prostate cancer compared to the
placebo group [30]. Also, prostate-specific antigen (PSA)-targeted
poxviral vaccines were well tolerated and associated with an
8.5-month improvement in median overall survival for patients
with metastatic castration-resistant prostate cancer [31]. Recent
advances for metastatic castration-resistant prostate cancer were
well summarized by Flemming [32].
Rini et al. randomized patients with metastastic renal cell carci-
noma into two cohorts, one receiving bevacizumab plus interferon
alpha (IFN-), the other IFN- only [33]. The combination treat-
ment led to a slightly prolonged overall survival time but did
not meet expectations, i.e., it was impossible to identify patient
subgroups benefiting from the combined treatment. Autologous
cytokine-induced killer cell immunotherapy was found to be
superior to combined IL-2 and IFN treatment in terms of 3-
year progression-free survival and overall survival in patient with
metastatic renal cell carcinoma [34].
For head and neck cancer patients, research efforts include
the development of the vaccine DRibble, stimulating tumour-
infiltrating T-lymphocytes [35] and immunotherapy of human
papilloma virus (HPV)-associated head and neck cancer [36]
amongst others.
4. Stereotactic ablative body radiotherapy combined with
immunotherapy
4.1. Preclinical results
Several studies have focused on the immunogenic response of
tumours to different dose schedules of radiotherapy. Lee et al.
observed that a single dose of ablative radiotherapy (20 Gy) gen-
erated a CD8+ T cell-dependent immunity leading to tumour
reduction and eradication of metastasis [37]. In comparison, mice
treated with 4 × 5 Gy initially responded to radiotherapy but
tumours relapsed over time. One possible explanation is that frac-
tionated low-dose radiotherapy may kill infiltrating CD8+ T cells
over time. However, when ablative radiotherapy (2 × 12 Gy) was
combined with ad-LIGHT-based immunotherapy, circulating cyto-
toxic T cells increased again and micrometastases were eradicated
[37]. Lugade et al. observed activated and expanded anti-tumour
CD8+ T cells in response to 5 fractions of 3 Gy, however with-
out resulting in tumour growth delay [38]. Although these studies
indicate that ablative radiotherapy is able to provoke a CD8+
T cell mediated immune response, most studies only detected
N.H. Rekers et al. / Cancer/Radiothérapie 18 (2014) 391–395 393















Fig. 1. Immunogenic cell death by stereotactic ablative body radiotherapy. Stereotactic ablative body radiotherapy can induce immunogenic cell death by the release of
tumour antigens and damage-associated molecular patterns (DAMPS), including high-mobility group protein B1 (HMGB1), adenosine triphosphate (ATP), Fas, ICAM-1 and
the exposure of calreticulin on the tumour cell surface. These factors promote uptake of dying cells by dendritic cells, cross-presentation of antigens to CD8+ T cells and
activation of cytotoxic T cells. However, it is unlikely that radiotherapy alone provides a sufficient anti-tumour immune response. The addition of immunotherapy that
stimulate dendritic cells, such as Flt3-L or that activate and prolong T cell responses, including anti-CTLA-4, anti-PD-1 or anti-CD137 can be combined with stereotactic































blative body radiotherapy to increase therapeutic potential and abscopal effects
ell; CTL: cytotoxic T lymphocyte.
n immune response after radiotherapy combined with different
mmunotherapies.
Several in vivo studies have investigated the combination of
adiotherapy with anti-CTLA-4 based immunotherapy. In a metas-
asizing breast cancer mouse model, a single dose (12 Gy) of
adiotherapy to the primary tumour combined with systemic
nti-CTLA-4 blocking antibody 9H10 immunotherapy decreased
etastatic burden, but the effect on the primary tumours was min-
mal. Two radiotherapy fractions of 12 Gy delivered to the primary
umour in combination with CTLA-4 blockade resulted in complete
egression of the irradiated tumour and metastases in the major-
ty of the mice, a response which was CD8+ T cell mediated [39].
ewan et al. tested different radiation regimens similar to stereo-
actic ablative body radiotherapy (1 × 20 Gy, 3 × 8 Gy or 5 × 6 Gy) in
ombination with anti-CTLA-4 in two poorly immunogenic tumour
odels and observed a growth delay of the irradiated tumour in all
reatment schedules [40]. However, an anti-tumour effect outside
he radiation field (abscopal effect) was only observed for the com-
ination of anti-CTLA-4 with fractionated radiotherapy (3 × 8 Gy).
Furthermore, Verbrugge et al. investigated a combination of
ntibodies against the immune modulators CD137 and PD-1, in
ombination with single dose (12 Gy) or fractionated (4 × 4 or 5 Gy)
adiotherapy in an orthotropic mice model [41]. Antibody com-
ination therapy with single dose radiotherapy was effective and
he combination with either 4 × 4 Gy or 4 × 5 Gy showed tumour
ejection rates of 40% and 80%, respectively. Furthermore, combina-
ion of single dose (12 Gy) radiotherapy with anti-PD-L1 treatment
ctivated a cytotoxic T cell response, which resulted in tumour
egression. An additional explanation for the local tumour control is
he reduction of local accumulation of myeloid-derived suppressor
ells [42].ore systematic way. SABR: stereotactic ablative body radiotherapy; DC: dendritic
Additionally, radiotherapy has been shown to reduce tumour
growth within and outside the radiation field when combined with
the dendritic cell growth factor Flt3-L [43], the human macrophage
inflammatory protein-1 alpha variant (ECI301) or with IL-2 admin-
istration [44–46]. Experiments with syngeneic tumour-bearing
mice showed that blocking annexin A5 resulted in decreased
dendritic cell clearance by macrophages, an improved tumour
immunogenicity, and combination with radiotherapy led to an
effective tumour growth inhibition [47]. Recently, radiotherapy
combined with adenoviral-mediated vaccination against the colo-
rectal cancer antigen GUCY2C resulted in a specific T cell response
leading to tumour eradication [48].
4.2. Clinical results
There are limited clinical results on the combination of Stereo-
tactic ablative body radiotherapy with immunotherapy. Postow
et al. were the first to observe an anti-tumour immunologic rejec-
tion of a metastatic lesion at distance from the irradiated site and
more reports followed [24,49–51]. In parallel, several phase II/III
clinical trials have been conducted leading to recent publications.
The phase I/II study in patients with metastatic castration-resistant
prostate cancer found ipilimumab with or without radiothe-
rapy to induce anti-tumour activity with disease control and
manageable side-effects [52]. However, Kwon et al. randomized
between ipilimumab or placebo after radiotherapy in patients with
metastatic castration-resistant prostate cancer and found no dif-
ference in terms of overall survival [53]. Several clinical studies
on combining immunotherapy (ipilimumab, PD-1 and PD-L1) with
(stereotactic ablative body) radiotherapy in diverse solid tumours
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ancer, (non-) small cell lung cancer, prostate and pancreatic can-
er) are currently being conducted and results are awaited eagerly
54].
. Conclusion
In conclusion, these data show that immunogenic cell death
aused by different strategies of radiotherapy can be used in
ombination with immunotherapy to induce a CD8+ T cell medi-
ted anti-tumour response, which leads to tumour control of
he irradiated tumour and often to tumour control outside the
adiation field, i.e., an abscopal effect in different preclinical mod-
ls. However, there is not yet a uniform combination strategy
or the best radiotherapy schedule/dose and immunotherapeutic
pproach. Furthermore, these preclinical studies often show no
ffect when immunotherapy is used without radiotherapy, sug-
esting that radiotherapy plays a key role as immunogenic trigger,
hich can be further enhanced when boosting the immune system.
linical studies are focusing on different immunotherapies, often
rying to activate or prolong specific anti-tumour T cell responses,
howing promising responses. The administration of immunother-
py adjuvantly to radiotherapy thus activating or prolonging T
ell responses specific to the irradiated tumour may increase the
mmune response inside the radiation field and at metastatic sides.
herefore, it may be important to start with a trigger received
rom stereotactic ablative body radiotherapy before administrating
mmunotherapy, because of the ‘priming’ role of radiotherapy in
his anti-tumour process.
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